Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease.
The pathological basis of dementia and visual hallucinations in Parkinson's disease (PD) is not yet fully understood. To investigate this further we have conducted a clinico-pathological study based on 30 post-mortem PD brains. PD cases were stratified into groups according to clinical characteristics as follows: (1) cognitively intact (n=9); (2) cases with severe dementia and visual hallucinations (n=12); (3) cases with severe dementia and no visual hallucinations (n=4); and (4) cases with severe visual hallucinations and no dementia (n=5). The extent of alpha-synuclein (alphaSyn), tau and amyloid beta peptide (Abeta) deposition was then examined in the CA2 sector of the hippocampus and in neocortical and subcortical areas known to subserve cognitive function. We find that dementia in PD is significantly associated with alphaSyn in the anterior cingulate gyrus, superior frontal gyrus, temporal cortex, entorhinal cortex, amygdaloid complex and CA2 sector of the hippocampus. Abeta in the anterior cingulate gyrus, entorhinal cortex, amygdaloid complex and nucleus basalis of Meynert is also associated with dementia as is tau in the CA2 sector of the hippocampus. alphaSyn burden in the amygdala is strongly related to the presence of visual hallucinations but only in those PD cases with concomitant dementia. Statistical analysis revealed that alphaSyn burden in the anterior cingulate gyrus could differentiate demented from non-demented PD cases with high sensitivity and specificity. We conclude that alphaSyn in limbic regions is related to dementia in PD as well as to visual hallucinations when there is an underlying dementia.
Kalaitzakis
M E
ME
Department of Clinical Neuroscience, Neuropathology Unit, Division of Neuroscience and Mental Health, Imperial College Healthcare NHS Trust, London, UK.
Christian
L M
LM
Moran
L B
LB
Graeber
M B
MB
Pearce
R K B
RK
Gentleman
S M
SM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000704:Analysis of Variance; D003704:Dementia / Q000209:etiology / Q000473:pathology*; D005260:Female; D006212:Hallucinations / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008032:Limbic System / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D011180:Postmortem Changes; D051844:alpha-Synuclein / Q000378:metabolism; D016875:tau Proteins / Q000378:metabolism
D016229:Amyloid beta-Peptides; D051844:alpha-Synuclein; D016875:tau Proteins